What is Emmaus Life Sciences?
Emmaus Life Sciences, formerly Emmaus Medical, Inc., is a biopharmaceutical firm focused on enhancing the lives of patients with rare and orphan diseases. Its primary therapeutic candidate is Endari, a treatment designed for sickle cell disease. The company is also exploring the development of therapies for other conditions, including diverticulosis, and is strategically expanding its market presence into the Middle East and North Africa regions. This focus positions Emmaus Life Sciences as a key player in addressing unmet medical needs.
How much funding has Emmaus Life Sciences raised?
Emmaus Life Sciences has raised a total of $79.5M across 6 funding rounds:
Private Equity
$1.7M
Private Equity
$20M
Debt
$30M
Share Placement
$2.4M
Share Placement
$25M
Debt
$350K
Private Equity (2016): $1.7M with participation from Korea Bio Medical Science Institute
Private Equity (2016): $20M, investors not publicly disclosed
Debt (2018): $30M supported by GPB Capital
Share Placement (2019): $2.4M featuring Vivozon Inc.
Share Placement (2020): $25M backed by Lincoln Park Capital Fund , LLC
Debt (2020): $350K with participation from PPP
Key Investors in Emmaus Life Sciences
Korea Bio Medical Science Institute
Korea Bio Medical Science Institute, operating through the EC21 platform, is a global B2B marketplace that connects buyers with manufacturers and suppliers, facilitating international trade and marketing for businesses across various sectors.
GPB Capital
GPB Capital is an alternative asset management firm based in New York, specializing in acquiring income-producing private companies and providing them with strategic planning, managerial insight, and capital to foster growth and profitability.
What's next for Emmaus Life Sciences?
The recent major strategic investment signals a pivotal growth phase for Emmaus Life Sciences. This capital injection is expected to accelerate the commercialization of Endari and fuel further research and development into new therapeutic areas. The company's expansion into new geographic markets, particularly the Middle East and North Africa, indicates a robust strategy for global reach and patient access. Emmaus Life Sciences appears poised to leverage this financing to solidify its market position and advance its pipeline of innovative treatments for significant health challenges.
See full Emmaus Life Sciences company page
